215 related articles for article (PubMed ID: 10979074)
41. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
42. Safety of St John's wort (Hypericum perforatum).
Jobst KA; McIntyre M; St George D; Whitelegg M
Lancet; 2000 Feb; 355(9203):575. PubMed ID: 10683027
[No Abstract] [Full Text] [Related]
43. Hyperforin: A natural lead compound with multiple pharmacological activities.
Li XX; Yan Y; Zhang J; Ding K; Xia CY; Pan XG; Shi YJ; Xu JK; He J; Zhang WK
Phytochemistry; 2023 Feb; 206():113526. PubMed ID: 36442576
[TBL] [Abstract][Full Text] [Related]
44. Optimization of Light Intensity, Temperature, and Nutrients to Enhance the Bioactive Content of Hyperforin and Rutin in St. John's Wort.
Kuo CH; Chou YC; Liao KC; Shieh CJ; Deng TS
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948004
[TBL] [Abstract][Full Text] [Related]
45. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line.
Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P
Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577
[TBL] [Abstract][Full Text] [Related]
46. St. John's wort: role of active compounds for its mechanism of action and efficacy.
Butterweck V; Schmidt M
Wien Med Wochenschr; 2007; 157(13-14):356-61. PubMed ID: 17704987
[TBL] [Abstract][Full Text] [Related]
47. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.
Barnes J; Anderson LA; Phillipson JD
J Pharm Pharmacol; 2001 May; 53(5):583-600. PubMed ID: 11370698
[TBL] [Abstract][Full Text] [Related]
48. Hypericum perforatum subspecies angustifolium shows a protective activity on the consequences of unavoidable stress exposure at lower doses than Hypericum perforatum perforatum.
Usai M; Leggio B; Grappi S; Nanni G; Gambarana C; Tolu P; Giachetti D; De Montis MG
Pharmacopsychiatry; 2003 Nov; 36(6):283-7. PubMed ID: 14663651
[TBL] [Abstract][Full Text] [Related]
49. A current review of the antimicrobial activity of Hypericum perforatum L.
Reichling J; Weseler A; Saller R
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S116-8. PubMed ID: 11518059
[TBL] [Abstract][Full Text] [Related]
50. Proapoptotic and prepulse inhibition (PPI) disrupting effects of Hypericum perforatum in rats.
Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE
J Ethnopharmacol; 2009 Apr; 122(3):561-6. PubMed ID: 19171186
[TBL] [Abstract][Full Text] [Related]
51. Hyperforin: more than an antidepressant bioactive compound?
Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
[TBL] [Abstract][Full Text] [Related]
52. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
53. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders.
Sarris J; Kavanagh DJ
J Altern Complement Med; 2009 Aug; 15(8):827-36. PubMed ID: 19614563
[TBL] [Abstract][Full Text] [Related]
54. The production of hypericins and hyperforin by in vitro cultures of St. John's wort (Hypericum perforatum).
Kirakosyan A; Sirvent TM; Gibson DM; Kaufman PB
Biotechnol Appl Biochem; 2004 Feb; 39(Pt 1):71-81. PubMed ID: 14521510
[TBL] [Abstract][Full Text] [Related]
55. Hyperforin-containing extracts of St John's wort fail to alter gene transcription in brain areas involved in HPA axis control in a long-term treatment regimen in rats.
Butterweck V; Winterhoff H; Herkenham M
Neuropsychopharmacology; 2003 Dec; 28(12):2160-8. PubMed ID: 12865894
[TBL] [Abstract][Full Text] [Related]
56. Treatment with Hypericum perforatum L. does not trigger decreased resistance in Staphylococcus aureus against antibiotics and hyperforin.
Hübner AT
Phytomedicine; 2003 Mar; 10(2-3):206-8. PubMed ID: 12725578
[TBL] [Abstract][Full Text] [Related]
57. Enrichment of hyperforin from St. John's wort (Hypericum perforatum) by pilot-scale supercritical carbon dioxide extraction.
Römpp H; Seger C; Kaiser CS; Haslinger E; Schmidt PC
Eur J Pharm Sci; 2004 Mar; 21(4):443-51. PubMed ID: 14998574
[TBL] [Abstract][Full Text] [Related]
58. Hyperforin.
Beerhues L
Phytochemistry; 2006 Oct; 67(20):2201-7. PubMed ID: 16973193
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
[TBL] [Abstract][Full Text] [Related]
60. St John's wort: a potential therapy for elderly depressed patients?
Vorbach EU; Arnoldt KH; Wolpert E
Drugs Aging; 2000 Mar; 16(3):189-97. PubMed ID: 10803859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
